The stock has multiplied 6 times during the last nine months. The purchase of shares by Dr. Frost in April at $0.05 has led to significant improvement in sentiments. Fundamentally, the company does not have much to show right now, though a recent article on seekingalpha has expressed positive sentiments about it. The author believes that the company has reduced losses over the past few years, and its product has a lot of potential. Investment by Dr. Frost also points to the potential in the products, and also the possible synergies which NIMU can offer for the other companies where Dr. Frost has a stake. The article mentions that there may be some synergies with OPKO Health (OPK). Further, Dr. Frost is known to be great at picking companies with high potential when they are available at low valuations. He also looks for collaboration between his companies. For example, he has substantial stake in Biozone (BZNE) which owns a high potential drug delivery technology (QuSomes). There is an agreement between Biozone and OPKO Health (OPK) for testing of the QuSomes technology. Though the possibility of a stake by OPKO could be far fetched, it cannot be ruled out either. However, it is important to remember that the company hardly has any revenues right now, and it needs to show some improvement in the fundamentals to justify the recent jump in market cap. It has appreciated by 328% in 2013, and has multiplied 6 times from its 52 week low of $0.05. Presence of Dr. Frost is surely reassuring, but ultimately fundamentals may start to weigh down on the stock. So it may be good to be a bit cautious after such a huge run up. News flow and results of the next few quarters will determine whether the stock will be able to cross the recent highs.
Market Data 
Markets 
